{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:02:48Z","timestamp":1772838168949,"version":"3.50.1"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>This Viewpoint discusses the potential benefits of making naltrexone available over the counter for the treatment of unhealthy alcohol use.<\/jats:p>","DOI":"10.1001\/jamapsychiatry.2025.3035","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:00:58Z","timestamp":1762358458000},"page":"7","source":"Crossref","is-referenced-by-count":1,"title":["Over-the-Counter Naltrexone to Address Unhealthy Alcohol Use"],"prefix":"10.1001","volume":"83","author":[{"given":"Olga","family":"Terechin","sequence":"first","affiliation":[{"name":"Mass General Brigham AMC Psychiatry Department, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia E.","family":"Matta","sequence":"additional","affiliation":[{"name":"Mass General Brigham AMC Psychiatry Department, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Mass General Brigham AMC Psychiatry Department, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"key":"yvp250028r2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-pharmtox-031323-115847","article-title":"Alcohol use disorder treatment: problems and solutions.","volume":"64","author":"Koob","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"yvp250028r3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/01.jcp.0000084030.22282.6d","article-title":"Targeted naltrexone for early problem drinkers.","volume":"23","author":"Kranzler","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"yvp250028r4","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","article-title":"Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health.","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"yvp250028r5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment.","volume":"14","author":"Jakubowski","year":"2020","journal-title":"J Addict Med"},{"issue":"3","key":"yvp250028r6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40265-021-01670-3","article-title":"Novel agents for the pharmacological treatment of alcohol use disorder.","volume":"82","author":"Burnette","year":"2022","journal-title":"Drugs"},{"issue":"5","key":"yvp250028r7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000146.pub5","article-title":"Nicotine replacement therapy versus control for smoking cessation.","volume":"5","author":"Hartmann-Boyce","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"yvp250028r1","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2023 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration; 2024. Accessed August 8, 2025. https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-annual-national-report"},{"key":"yvp250028r8","unstructured":"National Institute on Alcohol Abuse and Alcoholism. Rethinking drinking. Accessed August 8, 2025. https:\/\/rethinkingdrinking.niaaa.nih.gov"},{"key":"yvp250028r9","unstructured":"DailyMed. Naltrexone hydrochloride tablet, film coated. Updated February 15, 2024. Accessed August 25, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=49aa3d6d-2270-4615-aafa-b440859ab870"},{"key":"yvp250028r10","unstructured":"Center for Drug Evaluation and Research, US Food and Drug Administration. Drug application process for nonprescription drugs. Updated December 23, 2024. Accessed August 8, 2025. https:\/\/www.fda.gov\/drugs\/types-applications\/drug-application-process-nonprescription-drugs"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2840624\/jamapsychiatry_terechin_2025_vp_250028_1766508734.67091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:00:27Z","timestamp":1767801627000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2840624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.3035","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}